Genentech, Inc.

Curis, Inc.

Henry R Maun

Mark S Dennis

Robert A Lazarus

Xiaocheng Chen

James T Koerber

Lawren Wu

Mason Lu

Janet K Jackman

Tracy Staton

Saroja Ramanujan

Tangsheng Yi

Kathila Rajapaksa

Frederic J De Sauvage

Suzanna J Scales

Sarah G Hymowitz

Ivan Bosanac

Xiaohui Wen

Jose F Bazan

The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Anti-tryptase antibodies, compositions thereof, and uses thereof

Provided are novel, non-naturally occurring chagasin scaffold proteins derived from chagasin or chagasin-like protease inhibitor proteins. Also provided are libraries of non-naturally occurring chagasin scaffold proteins and methods of using such libraries to generate non-naturally occurring chagasin scaffold proteins that specifically bind to a target ligand. The present invention further provides methods of using non-naturally occurring chagasin protein scaffold that bind to a target ligand, including diagnostic and therapeutic compositions and methods. The invention also provides novel non-naturally occurring chagasin scaffold proteins that specifically bind low density lipoprotein receptor-related protein 6 (LRP6) and novel non-naturally occurring chagasin scaffold proteins that specifically bind vascular endothelial growth factor (VEGF).

Chagasin-based scaffold compositions, methods, and uses

The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.

Variant Hhip1 protein and methods and uses thereof

This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa ), its zymogen Factor VII (FVII). The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

FVIIa antagonists

Growing community of inventors

San Francisco, CA, United States of America

Henry R Maun